Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
non-pegylated liposomal doxorubicin + trastuzumab emtansine
- Development stage
- Unknown
- Lead developer
- MedSIR
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy consisting of non-pegylated liposomal doxorubicin and trastuzumab emtansine. Trastuzumab emtansine is an antibody-drug conjugate composed of the humanized anti-HER2 antibody trastuzumab linked to the cytotoxic agent DM1 (a maytansine derivative). It targets HER2-positive cancer cells, enters via receptor-mediated endocytosis, and releases DM1, which inhibits microtubule function leading to cell death. Non-pegylated liposomal doxorubicin is an anthracycline chemotherapy agent encapsulated in liposomes.
- Brand names
- none known as a unique combination product (Kadcyla is the brand for trastuzumab emtansine only)
- Other names
- trastuzumab emtansine plus non-pegylated liposomal doxorubicinT-DM1 + NPLD
02
Targets
TOP2A (DNA topoisomerase II)MicrotubuleDNAERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on non-pegylated liposomal doxorubicin + trastuzumab emtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on non-pegylated liposomal doxorubicin + trastuzumab emtansine.